Selenium nanoparticles and paclitaxel co-delivery by a PCL based nanofibrous scaffold to enhance melanoma therapy
Journal of Biomaterials Applications · 2025
DOI: 10.1177/08853282251330724 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biomaterials Applications, 2025. Verfasst von Maryam Doostan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Kermanshah University of Medical Sciences, Kermanshah, Iran. Hauptthemen laut MEDLINE: Polyesters, Selenium, Paclitaxel, Nanofibers. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 76 Literaturangaben. Gefördert von: Deputy for Research and Technology, Kermanshah University of Medical Sciences.
Abstract (Originalsprache)
The incidence of skin cancer has increased significantly in recent decades, highlighting the need for more effective treatments due to the limitations of traditional approaches. This study focused on creating a poly (ε-caprolactone) and chitosan (PCL/CS) nanofibrous scaffold loaded with selenium nanoparticles (Se NPs) and paclitaxel (PTX) to inhibit melanoma cell growth. The synthesized Se NPs, characterized by their uniform spherical shape and nano-scale size (∼120 nm), were incorporated into the scaffold. Then, the Se NPs and PTX were concurrently loaded into PCL/CS nanofibers at 5 wt%, which resulted in fibers with an average diameter of 253 ± 35 nm, presenting a ribbon-like morphology and absence of droplets/beads. The results indicated a high fluid absorption capacity, a wettability and high tensile strength of the produced scaffold. Moreover, the controlled release of the loaded compounds was provided over several days. Remarkably, high toxicity (>90%) and higher levels of apoptosis (>85%) were observed in A375 melanoma cells treated with the PTX-Se NPs PCL/CS scaffold. Moreover, the assessment of fibroblast growth and hemolysis confirmed the scaffold’s high level of biocompatibility. The PTX-Se NPs PCL/CS nanofibers exhibit favorable properties and strong anti-tumor efficacy, making them a promising scaffold for localized and selective chemotherapy in anti-melanoma treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kermanshah University of Medical Sciences, Kermanshah, Iran.
- Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
ORCID-Profile: Hassan Maleki
Förderung
- Deputy for Research and Technology, Kermanshah University of Medical Sciences
Zitieren
APA
Doostan, M., Rahmani Azar, A., & Maleki, H. (2025). Selenium nanoparticles and paclitaxel co-delivery by a PCL based nanofibrous scaffold to enhance melanoma therapy. Journal of Biomaterials Applications. https://doi.org/10.1177/08853282251330724
Vancouver
Doostan M, Rahmani Azar A, Maleki H. Selenium nanoparticles and paclitaxel co-delivery by a PCL based nanofibrous scaffold to enhance melanoma therapy. Journal of Biomaterials Applications. 2025. doi:10.1177/08853282251330724
BibTeX
@article{Doostan2025,
author = {Doostan, Maryam and Rahmani Azar, Ata'ollah and Maleki, Hassan},
title = {Selenium nanoparticles and paclitaxel co-delivery by a PCL based nanofibrous scaffold to enhance melanoma therapy},
journal = {Journal of Biomaterials Applications},
year = {2025},
doi = {10.1177/08853282251330724}
}
EUVIMED